Cytiva WHATMAN 93号湿强级定性滤纸

特色


品牌 其他品牌

Cytiva WHATMAN 93号湿强级定性滤纸1093-110 1093-125

93号(10um)滤纸的流速和截留颗粒值介于 1 号和 4 号纸之间。93 号滤纸也有分装包,分装可以贴在墙上或台面上,也可平放或者竖放在架子上并且可用作普通纸箱或作为便利的分配器。此外 93 号滤纸也提供独立的信封装,适用于单次使用。无论分包装还是信封装都清晰的标注了尺寸和数量。                                                           

1093-110 GR 93 11CM 100/PK
1093-111 GR 93 11CM 50×25 DSP/PK
1093-125 GR 93 12.5CM 100/PK
1093-126 GR 93 12.5CM 50×25 DSP/PK
1093-6212 GR 93 12.5CM 40×100/PK
1093-6215 GR 93 15CM 10×100/PK
1093-930 GR 93 58x58CM 500/PK
1093-935 GR 93 61x61CM 500/PK

Cytiva WHATMAN 93号湿强级定性滤纸1093-110 1093-125

Cytiva WHATMAN 4号快速定性滤纸

特色


品牌 其他品牌

Cytiva WHATMAN 4号快速定性滤纸1004-047 1004-110

4 号(25um孔径,厚度210um)滤纸对于粗颗粒和胶质沉淀物如氢氧化铁和氢氧化lv等具有快速过滤以及出色截留的能力。非常适用于常规生物试剂澄清或者分析中有机抽提物的快速过滤。也适用于高流速要求的空气污染物监测,但此时细颗粒物的截留不是重点。1/2 预折叠的滤纸为 4V。

1004-027 GR 4  2.7CM 400/PK
1004-041 GR 4  41MM 100/PK
1004-042 GR 4  4.25CM 100/PK
1004-047 GR 4  4.7CM 100/PK
1004-050 GR 4 5CM 100/PK
1004-055 GR 4 5.5CM 100/PK
1004-070 GR 4 7CM 100/PK
1004-090 GR 4 9CM 100/PK
1004-110 GR 4 11CM 100/PK
1004-125 GR 4 12.5CM 100/PK
1004-150 GR 4 15CM 100/PK
1004-185 GR 4 18.5CM 100/PK
1004-240 GR 4 24CM 100/PK
1004-270 GR 4 27CM 100/PK
1004-320 GR 4 32CM 100/PK
1004-400 GR 4 40CM 100/PK
1004-641 GR 4 1-3/8x7IN 1IN CORE 1/RL
1004-648 GR 4 38x114MM OD 63MM ID 1/RL
1004-917 GR 4 46x57CM 100/PK
1004-930 GR 4 58x58CM 100/PK

Cytiva WHATMAN 4号快速定性滤纸1004-047 1004-110

Whatman Polycap HD 囊式滤器, 2610T, 6703-3650, 2612T, 2611

特色

Whatman 沃特曼 Polycap HD 囊式滤器, 2610T, 6703-3650, 2612T, 2611

 

Whatman Polycap HD 囊式滤器, 2610T, 6703-3650, 2612T, 2611Whatman Polycap HD(高强度)是一种精心设计的产品,由于它的原料和生产方法使得它有很高的过滤效率和极好的纯度。
 
 
Whatman Polycap HD在过程应用中展示了它的优点,它的性能合适在粗过滤和最终的微孔滤膜之间起作用。
 
 
Whatman 沃特曼 Polycap HD 囊式滤器, 2610T, 6703-3650, 2612T, 2611

 
特性和优点
Whatman Polycap HD 囊式滤器, 2610T, 6703-3650, 2612T, 2611·100%聚丙烯过滤材质、支持物和外壳,可用于大范围的溶液、pH和温度
·高流速和高的保留力
·结构材料通过FDA允许用于食品接触
·可用121摄氏度20分钟蒸汽灭菌
·手动螺旋阀门可排出上游的气体,亦可用于注射或进样口
·有0.2、0.45,1.0、5.0和10.0μm孔径和多种接口
·在符合ISO要求的产地,10000级洁净室内生产
 
 
 
 
应用
·缓冲液
·洁净空气和气体设备
Whatman Polycap HD 囊式滤器, 2610T, 6703-3650, 2612T, 2611·化妆品和个人护理用品
·食品和饮料
·一般细颗粒过滤
·墨水和染料
·制药溶液
·感光乳胶和化妆水
·RO/UF/MF预滤膜
·试剂
·样品制备
·半导体和磁性介质
·溶剂
 
 
 
Whatman Polycap HD 囊式滤器, 2610T, 6703-3650, 2612T, 2611
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Whatman 沃特曼 Polycap HD 囊式滤器, 2610T, 6703-3650, 2612T, 2611

 
Whatman Polycap HD 囊式滤器, 2610T, 6703-3650, 2612T, 2611
Whatman 沃特曼 Polycap HD 囊式滤器, 2610T, 6703-3650, 2612T, 2611

Whatman Polycap HD 囊式滤器, 2610T, 6703-3650, 2612T, 2611Whatman Polycap HD 囊式滤器, 2610T, 6703-3650, 2612T, 2611Whatman Polycap HD 囊式滤器, 2610T, 6703-3650, 2612T, 2611
 

 

Whatman 沃特曼 Polycap HD 囊式滤器, 2610T, 6703-3650, 2612T, 2611
 

2610T, 6703-3610, 2611T, 2611, 6703-3650, 2612T, 6703-3611, 6703-3621, 2613T, 2614T, 2710, 6703-7510, 2711T, 6703-7550, 2712M, 2712T, 2712, 2713M, 2713, 6703-7511, 2713T, 2713, 6703-7521, 2714T, 2714, 2810T, 2810, 2812T, 2813T, 2813, 2814T
 
Whatman 沃特曼 Polycap HD 囊式滤器, 2610T, 6703-3650, 2612T, 2611

Beauveriolide III

Beauveriolide III;

Beauveriolide III 是小鼠巨噬细胞中脂滴形成的抑制剂。

Beauveriolide IIIamp;;

Beauveriolide III Chemical Structure

CAS No. : 221111-70-2

规格 是否有货
100 mg ; 询价 ;
250 mg ; 询价 ;
500 mg ; 询价 ;

* Please select Quantity before adding items.

生物活性

Beauveriolide III is an inhibitor of lipid droplet formation in mouse macrophages[1].

分子量

487.63

Formula

C27H41N3O5

CAS 号

221111-70-2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. ICHIJI NAMATAME, et al. Structure Elucidation of Fungal Beauveriolide III, a Novel Inhibitor of Lipid Droplet Formation in Mouse Macrophages.

millipore 90mm滤膜0.22um亲水性PVDF过滤膜GVWP09050


millipore 90mm滤膜0.22um亲水性PVDF过滤膜GVWP09050

说明: Durapore 表面滤膜,PVDF,亲水,0.22 µm,90 mm,白色,光面

商标名: Durapore

数量/包装: 50

应用: 除菌过滤生物溶液

滤膜材质: Hydrophilic PVDF

滤膜商标名: Durapore®

折射率: 1.42

水通量,mL/min x cm2: 6.7

23 °C 时的泡点: ≥3.45

zui高操作温度,°C: 85

滤膜类型: 表面滤膜

滤膜孔径,µm: 0.22

可润湿性: 亲水

滤膜直径,mm: 90

滤膜代码: GVWP

滤膜颜色: 白色

产品名称: Durapore 表面滤膜

滤膜表面: 光面

重量分析溶出物,%: 0.5

空气流速,L/min x cm2: 2

孔隙率 %: 70

技术指标

颜色:白色
表面:光面
厚度:125 µm
灭菌方法:高温高压灭菌(121 °C,1 bar)、EO 或 γ 射线
操作温度:85 °C
细菌内毒素:0.5 EU/mL
重量溶出物:< 0.5%

S-Pak网格滤膜0.22um微生物检测滤膜(无菌单独包装)GSWG047S6


S-Pak网格滤膜0.22um微生物检测滤膜(无菌单独包装)GSWG047S6

说明: S-Pak 滤膜,0.22µm 47mm 白色网格

商标名: S-Pak

数量/包装: 600

应用: 微生物分析

滤膜材质: Mixed Cellulose Esters

滤膜孔径,µm: 0.22

包装: S-Pak 滤膜,单独密封,带蓝色隔膜纸,无菌

滤膜直径,mm: 47

滤膜颜色: 白色

产品名称: S-Pak 无菌滤膜

滤膜表面: 网格

无菌: 无菌

S-Pak 网格滤膜,无菌独立包装,使用混合纤维素酯制成,经优化,适合对水或其它液体进行 MF 方法微生物分析。

类型 HA (0.45 µm) 适合整体大肠菌群或酵母菌和霉菌分析;类型 HC (0.7 µm) 适合粪大肠菌群分析,其中膜的漏斗型的孔增强了受压有机体回收率;类型 RA (1.2 µm) 适合酵母菌和霉菌分析,用于难以过滤的液体。

HAWG/HCWG 类型膜的质量证书证实符合标准的方法。

 

WHATMAN 934-AH玻璃纤维滤纸1827-125,1.5um玻璃纤维滤纸现货供应


WHATMAN 934-AH玻璃纤维滤纸1827-125,1.5um玻璃纤维滤纸现货供应

Grade 934-AH:1.5µm

这是一种改良的玻璃微纤维滤纸,无粘结剂,表面光滑,在更快的流速和高负载下,具有极好的颗粒物截留度,934-AH是*水质检测站每天测定总悬浮固体和总溶解性固体的标准过滤膜,它还可去除浑浊物和过滤培养基。zui近又称为国家标准方法中huang qu mei du su、赭曲霉毒素等样品过滤分离玻璃微纤维滤纸(1.5um 直径11cm),还可用于液闪计数、细胞培养和空气污染监测。

WHATMAN 934-AH玻璃纤维滤纸1827-125,1.5um玻璃纤维滤纸现货供应订购信息:

1827-021 934-AH 2.1CM 100/PK
1827-024 934-AH 2.4CM 100/PK
1827-025 934-AH 2.5CM 100/PK
1827-028 934-AH 2.8CM 100/PK
1827-030 934-AH 3.0CM 100/PK
1827-032 934-AH 3.2CM 100/PK
1827-035 934-AH 3.5CM 100/PK
1827-037 934-AH 3.7CM 100/PK
1827-042 934-AH 4.25CM 100/PK
1827-047 934-AH 4.7CM 100/PK
1827-055 934-AH 5.5CM 100/PK
1827-070 934-AH 7.0CM 100/PK
1827-082 934-AH 8.26CM 100/PK
1827-085 934-AH 8.5CM 100/PK
1827-090 934-AH 9.0CM 100/PK
1827-105 934-AH 10.5CM 100/PK
1827-110 934-AH 11CM 100/PK
1827-125 934-AH 12.5CM 100/PK
1827-150 934-AH 15CM 100/PK
1827-185 934-AH 18.5CM 100/PK
1827-240 934-AH 24CM 100/PK
1827-320 934-AH 32CM 100/PK
1827-808 934-AH 2x12IN 100/PK
1827-866 934-AH 8x10IN 100/PK
1827-889 934-AH 12x15IN 100/PK
1827-957 934-AH 19x28IN 100/PK

WHATMAN 934-AH玻璃纤维滤纸1827-125,1.5um玻璃纤维滤纸现货供应技术参数:

整包数量: 100 片
等级: Grade 934-AH1
液体中zui大颗粒保留: 1.5μm
常规厚度: 435μm
基本重量: 64g/m2
材质: 硼硅酸玻璃
属性特点: 高负载力
黏合剂类型: 无黏合剂

Agitoxin-2

Agitoxin-2;

Agitoxin-2 是 K+ 通道的阻断剂,其对 mKV1.3 和 mKV1.1 的 IC50 值分别为 201 pM 和 144 pM。

Agitoxin-2amp;;

Agitoxin-2 Chemical Structure

CAS No. : 168147-41-9

规格 是否有货
100 mg ; 询价 ;
250 mg ; 询价 ;
500 mg ; 询价 ;

* Please select Quantity before adding items.

生物活性

Agitoxin-2 is a K+ channel inhibitor, with IC50 values of 201 pM and 144 pM for mKV1.3 and mKV1.1, respectively)[1][2].

分子量

4090.87

Formula

C169H278N54O48S8

CAS 号

168147-41-9

Sequence Shortening

GVPINVSCTGSPQCIKPCKDAGMRFGKCMNRKCHCTPK (Disulfide bridge:Cys8-Cys28;Cys14-Cys33;Cys18-Cys35)

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

Solvent Solubility
In Vitro:;

H2O

Peptide Solubility and Storage Guidelines:

1.;;Calculate the length of the peptide.

2.;;Calculate the overall charge of the entire peptide according to the following table:

; Contents Assign value
Acidic amino acid Asp (D), Glu (E), and the C-terminal -COOH. -1
Basic amino acid Arg (R), Lys (K), His (H), and the N-terminal -NH2 +1
Neutral amino acid Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) 0

3.;;Recommended solution:

Overall charge of peptide Details
Negative (lt;0) 1.;;Try to dissolve the peptide in water first.
2.;;If water fails, add NH4OH (lt;50 μL).
3.;;If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (gt;0) 1.;;Try to dissolve the peptide in water first.
2.;;If water fails, try dissolving the peptide in a 10%-30% acetic acid solution.
3.;;If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0) 1.;;Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first.
2.;;For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.
参考文献
  • [1]. M L Garcia, et al. Purification and characterization of three inhibitors of voltage-dependent K+ channels from Leiurus quinquestriatus var. hebraeus venom. Biochemistry. 1994 Jun 7;33(22):6834-9.

    [2]. Raveendra Anangi, et al. Recombinant expression of margatoxin and agitoxin-2 in Pichia pastoris: an efficient method for production of KV1.3 channel blockers.

支原体预防试剂现货促销Invivogen Plasmocin™ prophylactic


支原体预防试剂现货促销Invivogen Plasmocin™ prophylactic

 

Plasmocin™

Mycoplasma Removal Agent

Plasmocin™ is used to cure cell lines infected by mycoplasma and related cell wall-less bacteria. 
支原体预防试剂现货促销Invivogen Plasmocin™ prophylacticPlasmocin™ can also be used as a routine addition in liquid media to prevent mycoplasma and more generally bacterial contamination in small and large animal cell cultures.
More info on Mycoplasma eradication

Plasmocin™ is a well-established antimycoplasma reagent. It contains two bactericidal components strongly active against mycoplasmas that allow their elimination in only 2 weeks. 
The first component acts on the protein synthesis machinery while the second acts on the DNA replication. These two specific and separate targets are found only in mycoplasmas and many other bacteria and are compley absent in eukaryotic cells.

Warning: InvivoGen's anti-mycoplasma products are suitable for research purposes only, and not for human or animal care.

 

  • Specifications
  • Docs
  • Contents
  • Description
  • Details
  • Citations

– Active on both free mycoplasmas and intracellular forms
– No resistance in liquid cultures of mycoplasmas
– No apparent adverse effect on cellular metabolism
– Active at low concentrations on a broad range of Gram positive and negative bacteria
– Eliminates mycoplasma in as little as 2 weeks
– Treat up to 25 cell lines in T75

 

  • TDS Plasmocin™ prophylactic : 25 mg (10 x 1 ml) (ant-mpp)
  • TDS Plasmocin™ treatment : 50 mg (2 x 1 ml) (ant-mpt)
  • MSDS Plasmocin™ prophylactic : 25 mg (10 x 1 ml) (ant-mpp) , 50 mg (2 x 1 ml) (ant-mpt)

 

Plasmocin™ is provided as a yellow solution at different concentrations:

–  25 mg/ml (Plasmocin™Treatment)

–  2.5 mg/ml (Plasmocin™ Prophylactic)

In contrast to other anti-mycoplasma compounds, Plasmocin™ is active on both free mycoplasmas and intracellular forms. This advantage is conferred by one component of Plasmocin™ which is actively transported into mammalian cells. It ensures that following treatment with Plasmocin™ a cell culture is not reinfected by mycoplasmas released from intracellular compartments of infected cells.

In all animal cell lines tested to date, even at five times the working concentration, no apparent adverse effect on cellular metabolism is observed.

No resistance in liquid cultures of mycoplasmas has ever been identified in repeated experiments attempting to measure the mutation rate. Therefore, development of resistant mycoplasma strains is virtually eliminated.

Plasmocin™ is also active at low concentrations on a broad range of Gram positive and Gram negative bacteria that are otherwise resistant to the mixture of streptomycin and penicillin, and exhibits no toxicity in eukaryotic cells.

Many cell lines infected by mycoplasmas have been successfully treated with Plasmocin™, including embryonic stem cells, hybridomas and retrovirus packaging cells.

Comparison of the most common anti-mycoplasma agents [1-3]

Product Supplier Treatment Ease of use Efficacy Cytotoxicity Resistance
BM-Cyclin Roche 3 weeks +++ + +/-
Ciprobay Bayer 12 to 20 days + ++ +/- +
MRA ICN 1 to 2 weeks + ++ +/- +
Plasmocin InvivoGen 2 weeks + +++ +/-

Antibiotics commonly used in cell culture are inactive on mycoplasma (e.g. penicillins and streptomycin). Three classes of antibiotics have been shown to kill mycoplasma at relatively low concentrations: tetracyclines, macrolides and quinolones. Tetracyclines and macrolides block the protein synthesis by interfering with ribosome translation, while quinolones inhibit the replication of bacterial DNA.
Several antibiotics are commercially available for the removal of mycoplasma: BM-cyclin (Roche) contains a macrolide and a tetracycline, Ciprobay (Bayer, available only with a prescription) and MRA (ICN) are both quinolones. Plasmocin™ is the only antimycoplasma reagent that combines a macrolide and a quinolone. Unlike BM-Cyclin that requires the sequential and cyclic use of 2 antibiotics, Plasmocin™ is ready-to-use and can be added to the culture medium directly. Furthermore, the 2 antibiotics in Plasmocin™ act on separate targets blocking protein synthesis and DNA replication, whereas the 2 antibiotics in BM-Cyclin are both inhibitors of protein synthesis. Therefore, Plasmocin™ is more effective in removing mycoplasma and prevents the appearance of resistant strains. In contrast to other anti-mycoplasma compounds, Plasmocin™ is active on both free mycoplasma as well as intracellular forms. This advantage is conferred by one component of Plasmocin™ which is actively transported into mammalian cells. It ensures that following treatment with Plasmocin™ a cell culture is not reinfected by mycoplasma released from intracellular compartments of infected cells. To date, no consistent and permanent alterations that affect the eukaryotic cells during and after the treatment have been detected[1].

1. Uphoff CC, Drexler HG., 2005. Eradication of mycoplasma contaminations. Methods Mol Biol. 290:25-34.
2. Somasundaram C. et al., 1992. Use of ciprofloxacin and BM-Cyclin in mycoplasma decontamination.In Vitro Cell Dev Biol. 28A(11-12):708-10
3. Drexler HG. et al., 1994. Treatment of mycoplasma contamination in a large panel of cell cultures. In vitro Cell Dev Biol Anim. 30A(5):344-7

 

Recent articles using Plasmocin™

 

 

  • 2012 – J Virol Methods., Epub ahead of print
    Mycoplasma removal: Simple curative methods for viral supernatants.
    Baronti C, Pastorino B, Charrel R, de Lamballerie X
  • 2011 – Mol Pharmacol., 80(6):1066-75
    Ca2+/calmodulin-dependent kinase (CaMK) signaling via CaMKI and AMP-activated protein kinase contributes to the regulation of WIPI-1 at the onset of autophagy.
    Pfisterer SG, Mauthe M, Codogno P, Proikas-Cezanne T
  • 2011 – J Immunol., 186(12):6822-6829
    Tumor cell programmed death ligand 1-mediated T cell suppression is overcome by coexpression of CD80.
    Haile ST, Bosch JJ, Agu NI, Zeender AM, Somasundaram P, Srivastava MK, Britting S, Wolf JB, Ksander BR, Ostrand-Rosenberg S
  • 2012 – J. Biol. Chem., 287: 8082 – 8091
    Loss of lysosomal ion channel transient receptor potential channel mucolipin-1 (TRPML1) leads to cathepsin B-dependent apoptosis.
    Colletti GA, Miedel MT, Quinn J, Andharia N, Weisz OA, Kiselyov K
  • 2012 – Immunity, 36(3):464-476
    An NLRP7-containing inflammasome mediates recognition of microbial lipopeptides in human macrophages.
    Khare S, Dorfleutner A, Bryan NB, Yun C, Radian AD, de Almeida L, Rojanasakul Y, Stehlik C

 

 

ORDERING

Plasmocin™ prophylactic

Description Removal agent to prevent mycoplasma contamination
Cat. Code ant-mpp
Unit Size 25 mg (10 x 1 ml)
Price Please contact our distributor

 

  • TDS
  • MSDS

 

Plasmocin™ treatment

Description Removal agent to eliminate mycoplasmas
Cat. Code ant-mpt
Unit Size 50 mg (2 x 1 ml)
Price Please contact our distributor

 

  • TDS
  • MSDS

 

YOU MAY ALSO NEED

PlasmoTest™ Detection of mycoplasma contamination in cell culture kit
Normocin™ Antimicrobial agent for prevention against Mycoplasma, Bacteria and Fungi
Fungin™ Antimicrobial agent for prevention and elimination of Fungi
G418 Selection antibiotic for the neo gene
Puromycin Selection antibiotic for the pac gene

进口支原体清除剂现货促销Invivogen Plasmocin™ treatmen


进口支原体清除剂现货促销Invivogen Plasmocin™ treatmen

 

Plasmocin™

Mycoplasma Removal Agent

Plasmocin™ is used to cure cell lines infected by mycoplasma and related cell wall-less bacteria. 
进口支原体清除剂现货促销Invivogen Plasmocin™ treatmenPlasmocin™ can also be used as a routine addition in liquid media to prevent mycoplasma and more generally bacterial contamination in small and large animal cell cultures.
More info on Mycoplasma eradication

Plasmocin™ is a well-established antimycoplasma reagent. It contains two bactericidal components strongly active against mycoplasmas that allow their elimination in only 2 weeks. 
The first component acts on the protein synthesis machinery while the second acts on the DNA replication. These two specific and separate targets are found only in mycoplasmas and many other bacteria and are compley absent in eukaryotic cells.

Warning: InvivoGen's anti-mycoplasma products are suitable for research purposes only, and not for human or animal care.

 

  • Specifications
  • Docs
  • Contents
  • Description
  • Details
  • Citations

– Active on both free mycoplasmas and intracellular forms
– No resistance in liquid cultures of mycoplasmas
– No apparent adverse effect on cellular metabolism
– Active at low concentrations on a broad range of Gram positive and negative bacteria
– Eliminates mycoplasma in as little as 2 weeks
– Treat up to 25 cell lines in T75

 

  • TDS Plasmocin™ prophylactic : 25 mg (10 x 1 ml) (ant-mpp)
  • TDS Plasmocin™ treatment : 50 mg (2 x 1 ml) (ant-mpt)
  • MSDS Plasmocin™ prophylactic : 25 mg (10 x 1 ml) (ant-mpp) , 50 mg (2 x 1 ml) (ant-mpt)

 

Plasmocin™ is provided as a yellow solution at different concentrations:

–  25 mg/ml (Plasmocin™Treatment)

–  2.5 mg/ml (Plasmocin™ Prophylactic)

In contrast to other anti-mycoplasma compounds, Plasmocin™ is active on both free mycoplasmas and intracellular forms. This advantage is conferred by one component of Plasmocin™ which is actively transported into mammalian cells. It ensures that following treatment with Plasmocin™ a cell culture is not reinfected by mycoplasmas released from intracellular compartments of infected cells.

In all animal cell lines tested to date, even at five times the working concentration, no apparent adverse effect on cellular metabolism is observed.

No resistance in liquid cultures of mycoplasmas has ever been identified in repeated experiments attempting to measure the mutation rate. Therefore, development of resistant mycoplasma strains is virtually eliminated.

Plasmocin™ is also active at low concentrations on a broad range of Gram positive and Gram negative bacteria that are otherwise resistant to the mixture of streptomycin and penicillin, and exhibits no toxicity in eukaryotic cells.

Many cell lines infected by mycoplasmas have been successfully treated with Plasmocin™, including embryonic stem cells, hybridomas and retrovirus packaging cells.

Comparison of the most common anti-mycoplasma agents [1-3]

Product Supplier Treatment Ease of use Efficacy Cytotoxicity Resistance
BM-Cyclin Roche 3 weeks +++ + +/-
Ciprobay Bayer 12 to 20 days + ++ +/- +
MRA ICN 1 to 2 weeks + ++ +/- +
Plasmocin InvivoGen 2 weeks + +++ +/-

Antibiotics commonly used in cell culture are inactive on mycoplasma (e.g. penicillins and streptomycin). Three classes of antibiotics have been shown to kill mycoplasma at relatively low concentrations: tetracyclines, macrolides and quinolones. Tetracyclines and macrolides block the protein synthesis by interfering with ribosome translation, while quinolones inhibit the replication of bacterial DNA.
Several antibiotics are commercially available for the removal of mycoplasma: BM-cyclin (Roche) contains a macrolide and a tetracycline, Ciprobay (Bayer, available only with a prescription) and MRA (ICN) are both quinolones. Plasmocin™ is the only antimycoplasma reagent that combines a macrolide and a quinolone. Unlike BM-Cyclin that requires the sequential and cyclic use of 2 antibiotics, Plasmocin™ is ready-to-use and can be added to the culture medium directly. Furthermore, the 2 antibiotics in Plasmocin™ act on separate targets blocking protein synthesis and DNA replication, whereas the 2 antibiotics in BM-Cyclin are both inhibitors of protein synthesis. Therefore, Plasmocin™ is more effective in removing mycoplasma and prevents the appearance of resistant strains. In contrast to other anti-mycoplasma compounds, Plasmocin™ is active on both free mycoplasma as well as intracellular forms. This advantage is conferred by one component of Plasmocin™ which is actively transported into mammalian cells. It ensures that following treatment with Plasmocin™ a cell culture is not reinfected by mycoplasma released from intracellular compartments of infected cells. To date, no consistent and permanent alterations that affect the eukaryotic cells during and after the treatment have been detected[1].

1. Uphoff CC, Drexler HG., 2005. Eradication of mycoplasma contaminations. Methods Mol Biol. 290:25-34.
2. Somasundaram C. et al., 1992. Use of ciprofloxacin and BM-Cyclin in mycoplasma decontamination.In Vitro Cell Dev Biol. 28A(11-12):708-10
3. Drexler HG. et al., 1994. Treatment of mycoplasma contamination in a large panel of cell cultures. In vitro Cell Dev Biol Anim. 30A(5):344-7

 

Recent articles using Plasmocin™

 

 

  • 2012 – J Virol Methods., Epub ahead of print
    Mycoplasma removal: Simple curative methods for viral supernatants.
    Baronti C, Pastorino B, Charrel R, de Lamballerie X
  • 2011 – Mol Pharmacol., 80(6):1066-75
    Ca2+/calmodulin-dependent kinase (CaMK) signaling via CaMKI and AMP-activated protein kinase contributes to the regulation of WIPI-1 at the onset of autophagy.
    Pfisterer SG, Mauthe M, Codogno P, Proikas-Cezanne T
  • 2011 – J Immunol., 186(12):6822-6829
    Tumor cell programmed death ligand 1-mediated T cell suppression is overcome by coexpression of CD80.
    Haile ST, Bosch JJ, Agu NI, Zeender AM, Somasundaram P, Srivastava MK, Britting S, Wolf JB, Ksander BR, Ostrand-Rosenberg S
  • 2012 – J. Biol. Chem., 287: 8082 – 8091
    Loss of lysosomal ion channel transient receptor potential channel mucolipin-1 (TRPML1) leads to cathepsin B-dependent apoptosis.
    Colletti GA, Miedel MT, Quinn J, Andharia N, Weisz OA, Kiselyov K
  • 2012 – Immunity, 36(3):464-476
    An NLRP7-containing inflammasome mediates recognition of microbial lipopeptides in human macrophages.
    Khare S, Dorfleutner A, Bryan NB, Yun C, Radian AD, de Almeida L, Rojanasakul Y, Stehlik C

 

 

ORDERING

Plasmocin™ prophylactic

Description Removal agent to prevent mycoplasma contamination
Cat. Code ant-mpp
Unit Size 25 mg (10 x 1 ml)
Price Please contact our distributor

 

  • TDS
  • MSDS

 

Plasmocin™ treatment

Description Removal agent to eliminate mycoplasmas
Cat. Code ant-mpt
Unit Size 50 mg (2 x 1 ml)
Price Please contact our distributor

 

  • TDS
  • MSDS

 

YOU MAY ALSO NEED

PlasmoTest™ Detection of mycoplasma contamination in cell culture kit
Normocin™ Antimicrobial agent for prevention against Mycoplasma, Bacteria and Fungi
Fungin™ Antimicrobial agent for prevention and elimination of Fungi
G418 Selection antibiotic for the neo gene
Puromycin Selection antibiotic for the pac gene

C3bot(154-182)

C3bot(154-182);

C3bot(154-182) 是一种 C3 肽,通过改善下行纤维束的再生生长来增强脊髓损伤的恢复能力。C3bot(154-182) 有潜力促进中枢神经系统损伤后的轴突保护和/或修复以及功能恢复。

C3bot(154-182)amp;;

C3bot(154-182) Chemical Structure

CAS No. : 1246280-79-4

规格 是否有货
100 mg ; 询价 ;
250 mg ; 询价 ;
500 mg ; 询价 ;

* Please select Quantity before adding items.

生物活性

C3bot(154-182) is a C3 peptide enhances recovery from spinal cord injury by improving regenerative growth of descending fiber tracts. C3bot(154-182) represents a promising tool to foster axonal protection and/or repair, as well as functional recovery after traumatic CNS injury[1].

体外研究
(In Vitro)

C3bot(154-182) stimulates regenerative growth of raphespinal fibers and improves serotonergic input to lumbar α-motoneurons[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

3058.51

Formula

C137H221N37O40S

CAS 号

1246280-79-4

Sequence Shortening

VAKGSKAGYIDPISAFAGQLEMLLPRHST

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

Solvent Solubility
In Vitro:;

H2O

Peptide Solubility and Storage Guidelines:

1.;;Calculate the length of the peptide.

2.;;Calculate the overall charge of the entire peptide according to the following table:

; Contents Assign value
Acidic amino acid Asp (D), Glu (E), and the C-terminal -COOH. -1
Basic amino acid Arg (R), Lys (K), His (H), and the N-terminal -NH2 +1
Neutral amino acid Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) 0

3.;;Recommended solution:

Overall charge of peptide Details
Negative (lt;0) 1.;;Try to dissolve the peptide in water first.
2.;;If water fails, add NH4OH (lt;50 μL).
3.;;If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (gt;0) 1.;;Try to dissolve the peptide in water first.
2.;;If water fails, try dissolving the peptide in a 10%-30% acetic acid solution.
3.;;If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0) 1.;;Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first.
2.;;For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.
参考文献
  • [1]. Francesco Boato, et al. C3 peptide enhances recovery from spinal cord injury by improved regenerative growth of descending fiber tracts. J Cell Sci. 2010 May 15;123(Pt 10):1652-62.

MF混合纤维素滤膜AAWP04700优势供应,AAWP04700滤膜现货供应


MF混合纤维素滤膜AAWP04700优势供应,AAWP04700滤膜现货供应

说明: MF-Millipore 表面滤膜,混合纤维素酯,亲水,0.8 µm,47 mm,白色,光面

商标名: MF-Millipore

数量/包装: 100

滤膜材质: Mixed Cellulose Esters

滤膜商标名: MF-Millipore

折射率: 1.51

水通量,mL/min x cm2: 190

23 °C 时的泡点: ≥1.10 bar

zui高操作温度,°C: 75

滤膜类型: 表面滤膜

滤膜孔径,µm: 0.8

可润湿性: 亲水

滤膜直径,mm: 47

滤膜代码: AAWP

滤膜颜色: 白色

产品名称: MF-Millipore 表面滤膜

滤膜表面: 光面

重量分析溶出物,%: 4

厚度,µm: 180

空气流速,L/min x cm2: 16

孔隙率 %: 82

Swinnex换膜过滤器现货供应,Swinnex换膜过滤器价格


Swinnex换膜过滤器现货供应,Swinnex换膜过滤器价格 sx0004700 SX0002500 SX0001300

用于对注射器分配的少量液体进行超清洗或除菌。 用导管将 Swinnex 47 mm 过滤器与加压容器或自动注入机相连可过滤较大容量的液体。

应用: 生命科学的研究与开发,制药业及质检,医院制剂

技术指标

  Swinnex 13 Swinnex 25 Swinnex 47
材料
外壳 聚丙烯 聚丙烯 聚丙烯
密封材质 Silicone Silicone Silicone
zui大压差,bar (psi)
  3.5 (50) 3.5 (50) 5 (75)
尺寸
长度,cm (in) 3.5 3.7 5.4
直径,cm (in) 1.7 3.2 5.7
滤膜直径, mm 13 25 47
预过滤膜直径, mm 10 (thick depth prefilter) 22 (thick depth prefilter) 42 (thick depth prefilter) or 47 (membrane prefilter)
过滤面积, cm2 0.7 3.4 13.8
 
进口接头 阴 Luer-Lok 接头 阴 Luer-Lok 接头 1/4″ NPTM,带阴 Luer 滑动内接头
出口接头 阳 luer 滑动接头 阳 luer 滑动接头 1/4″ 软管接口,带阴 Luer 滑动内接头
灭菌 可装膜后高压高温灭菌
*在高温高压情况下,注射器的容量小于 10mL 时,采用锁定进口连接以防止泄漏